Research Reports

Stakeholder Opinions: Percutaneous Coronary Intervention - Adverse events with drug-eluting stents demand a new safety standard

Thu, 01 May 2008 16:46:33 -0400

Introduction
While drug eluting stents have been successful in reducing the rate of restenosis following percutaneous coronary intervention, there have been safety scares over a new problem: “in-stent thrombosis”. Opinion leaders are divided over the gravity of this problem, but positive safety data are required to restore physician confidence in drug eluting stents.

Scope
Review of the acute coronary syndromes (ACS) – the indication that drives the PCI market.

Opinion leader commentary on guideline developments and key clinical trials.

Review of the key drug classes used in conjunction with PCI and the current opinion on facilitated PCI.

Opinion leader discussion of currently marketed stents, key clinical trials in stents, and the evolution from bare metal to drug eluting stents.

Report Highlights
Since the introduction of PCI the procedure rate has increased dramatically making it one of the most common interventional procedures for heart disease. Use of PCI differs across the major markets, with this more aggressive revascularization strategy receiving greatest uptake in the United States, where coronary artery disease is most prevalent.

Evidence that facilitated PCI improves clinical outcomes remains inconclusive, although opinion leaders consider the premature interruption of ASSENT-4 to advise against facilitation with thrombolytics; the ACC/AHA guidelines suggest facilitation only in “high risk” patients, whereas the ESC say they find no evidence to recommend it at all.

While drug eluting stents have been successful in reducing restenosis rates from 20-30% to single digits, there have been safety scares over a new problem: “in-stent thrombosis”. Cordis’s Cypher and Boston Scientific’s Taxus have received some unfavourable press, but physicians are still enthusiastic about Abbott’s new stent, Xience.

Reasons to Purchase
Understand the PCI market, the driving indications and the drug classes prescribed in PCI patients.

Gain physician opinion on current treatment practice and how it might evolve.

Understand the negative publicity which has caused the robust drug eluting stent market to falter.

Impact of Pharmacogenomics on Public Healthcare Policy

Tue, 01 Apr 2008 09:42:28 -0400

During the last fifteen years tremendous advances have been made in deciphering the genetic coding of a variety of species from invertebrates, vertebrates and finally man through the formal initiation of the Human Genome Project in October 2000 and its completion in 2003. This information has helped to increase our understanding of how genetics has a pivotal role in the predisposition of many diseased states, the progression of a course of a disease, as well as a patient’s response to a drug, or lack of it. Now in the 21st Century there is a growing trend towards the development of personalized medicine – the right drug for the right individual.

Examine the rapidly advancing fields of pharmacogenomics and pharmacogenetics, and measure the impact of pharmacogenomic techniques on reimbursement and health economics with this new report.

The Cardiovascular Disorders Market Outlook to 2012

Wed, 19 Mar 2008 14:29:14 -0400

Top five reasons to order your copy today
• Assess patient potential, treatment trends and sales patterns across major cardiovascular indications with this report’s analysis of epidemiological studies, unmet medical need, and economic imperatives for stakeholders.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of AstraZeneca, BMS, Daiichi Sankyo, GSK, Merck, Novartis, Pfizer, Sanofi-Aventis and Servier.
• Discover the market dynamics of the cardiovascular area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting R&D.
• Compare the future prospects of key players and forecast sales of leading products across major indications to 2012 with this report’s analysis of sales focus by drug class, currently marketed portfolios, R&D pipelines, and trends in promotional spend for key brands.
• Identify the strategies that offer the greatest success potential within the future cardiovascular market and understand the challenges currently facing companies within this therapeutic area.

Key issues examined in this report...
• Cardiac therapies. Heart failure treatments have become a focal point for cardiovascular drug developments. However, doubts remain over whether the marginal benefits offered by such medicines will be sufficient to generate and sustain high levels of revenue.
• Combination drugs. Although combination drugs failed to accrue strong sales growth in 2007, the growing acceptance of combination dyslipidemic therapies amongst payors and physicians will favour Merck’s Vytorin/Inegy and Novartis’ newly launched combination product Exforge (amlodipine/losartan)
• Empty pipelines. Currently marketed portfolios have taken on greater importance in light of weak late stage pipelines among players such as Merck, BMS and AstraZeneca. This lack of new revenue sources is forecast to depress future growth in the cardiovascular market.
• Market leaders. Few leading companies are expected to retain their presence in the cardiovascular market, with some major players set to experience drastic declines in revenue over the forecast period.

2008 Trends to Watch: Pharmaceutical Technology

Wed, 19 Mar 2008 14:26:13 -0400

Introduction

Technology markets are changing fast. This brief identifies and tracks the key forces shaping the prospects for your business. In this piece, Datamonitor's analyst specializing in pharmaceutical technology will outline the changes in the market, explain which trends will have the biggest impact, and highlight who will benefit from the fast-paced developments in pharmaceutical technology.

Scope

An overview of the challenges facing the life science industry in 2008 Datamonitor's take on the technology priorities of pharmaceutical and biotechnology companies Strategies to help technology vendors penetrate the life science industry.

Highlights

As the specter of generic competition grows, streamlining operations to reduce costs and time-to-market of a drug will be a top priority for pharmaceutical companies. The life science industry must embrace technology solutions as it shifts away from the "blockbuster drug" business model. Data management is a key issue affecting the life sciences. As drug regulatory agencies demand more clinical and post-market data, clinical IT solutions will become crucial to the industry.

Reasons to Purchase

Learn about the top trends in the life science industry in 2008 Identify strategies for expanding business opportunities in the life science industry Tailor your go-to-market strategy to address critical issues facing pharmaceutical and biotechnology companies.

Pharmaceutical Pricing and Reimbursement: Strategies for market access across the US, Europe, Japan and other key geographies

Wed, 19 Mar 2008 13:42:37 -0400

The global pharmaceutical pricing and reimbursement environment is notoriously complex and continuously changing. Pharma companies must implement strategic pricing assessments across global markets and product lifecycle phases in order to develop effective pricing policies. By incorporating such assessments into portfolio evaluations and lifecycle planning, companies can enhance their understanding of potential price profiles for individual drugs and optimise future returns.
Use this report to develop effective pricing strategies based upon this report’s unique market forecasts for future pricing scenarios in key markets and understand the major issues affecting the global pricing landscape.

Emerging markets series: Benchmarking key countries Brazil, Russia, India, China and Turkey

Wed, 19 Mar 2008 13:35:28 -0400

Declining growth rates in developed markets mean many pharmaceutical companies are turning their attention to developing markets. Economic growth and healthcare reforms means many non-traditional markets are experiencing tremendous growth. This report from Datamonitor provides insight into the key macroeconomic and healthcare trends that are impacting markets in Brazil, Russia, India, China and Turkey. Whilst non of these markets provide the ideal market for Western businesses, their increasing transition towards a more westernized model means that they offer much potential.
Gain insight into the opportunities available for international companies in these markets and assess the challenges that they must overcome in order to succeed.

Generics Series: Key trends and events in the 7 major markets

Wed, 19 Mar 2008 13:34:18 -0400

The generics market is growing, driven by rising healthcare costs and fed by a steady stream of patent expiries. Levels of generic uptake vary widely across the 7 major markets, with important implications for industry strategy.
Use this report to gain an understanding of the major drivers and resistors to generic growth in each of the 7 major markets.

Examining the Global Market for Electronic Health Records (Market Focus)

Zachary Pentel — Tue, 09 Oct 2007 11:59:00 -0400

Introduction
Electronic health records (EHRs) will be the cornerstone of healthcare technology. The design, selection and implementation of EHRs, therefore, will be extremely important for healthcare institutions.

Scope

Identifies the key forces driving the adoption of EHRs
Analyzes the crucial issues that will impede the uptake of EHRs
Describes the impact EHRs will have on healthcare

Report Highlights

Electronic health records will become a “must-have” for healthcare organizations
EHR adoption will be inevitable due to internal as well as external factors
Cost is the most significant, but not the only, barrier to adoption

Reasons to Purchase

Understand the institutional factors influencing technology decision-making
Align product messaging with what will resonate best with healthcare organizations
Shape product development to meet the business pain points of the healthcare market

Innovations in Cardiovascular Disease Management: Latest surgical procedures, drugs and medical devices

Zachary Pentel — Tue, 09 Oct 2007 11:38:17 -0400

Despite significant advances in prevention and treatment, cardiovascular disease remains the leading cause of death in economically advanced countries. The developing world has also begun to experience a disconcerting growth in prevalence, where the insurgence of CVD has exacerbated the risk factors associated with indigenous communicable diseases.

Keeping pace with epidemiological change in both the developed and developing world constitutes the overriding challenge for industrial players, and involves successfully integrating into localised healthcare systems and reimbursement structures, in addition to remaining aligned with product demand. In the medical device, pharmaceutical and biotechnology industries, this challenge is being met with a focus on products that reduce adverse effects, improve patient outcomes and extend the range of formulations for existing indications.

‘Innovations in Cardiovascular Disease Management’ is a new report published by Business Insights that will examine the major developments shaping the future of the cardiovascular industry. This report will analyse the future potential of new and emerging products from the medical device, pharmaceutical and biotechnology sectors, and measure their likely impact upon the existing market.

The extent to which these products can stimulate the growth and development of the future market will also be assessed. Use this report to evaluate the potential of new and emerging products in the treatment of cardiovascular diseases, assess the strength of competitor pipelines and identify future market opportunities...

Disease Management and Drug Adherence: Strategies to support patients and enhance treatment persistence

Zachary Pentel — Tue, 09 Oct 2007 11:35:10 -0400

Introduction

Failure to take medication as prescribed significantly increases the risk that patients will experience complications resulting in injury or death, and propagate higher healthcare costs overall. The medical establishment's approach to adherence is changing as it becomes clear that the responsibility of achieving adherence is not solely the patient's, but rather is shared among stakeholders.

Scope

Analysis of what is meant by adherence, how adherent behavior of measured and the factors that impact whether a patient follows treatment advice
Examination of the factors individual, economic and societal factors that influence whether a patient will remain adherent
Assessment of the healthcare trends that are impacting adherence to drugs worldwide In depth case study analysis of programs created by governments and industry in order to foster adherence in chronically ill patient populations

Highlights

Physicians who do not take the time to understand their patients can negatively impact adherence by failing to take into consideration factors that may make it difficult for patients to follow a medication regimen. This can lead to physicians prescribing treatments that are prohibitively complex or missing opportunities to provide support services. The ideal approach would involve collaboration between a variety of stakeholders, including physicians, patient groups, payers and the pharmaceutical industry. However, collaboration has proven to be complicated, not least of all because there is little or no consensus about how to define or measure adherence. Reaching customers through customized interactions will help to make them feel as though they are valued and understood by the company. Furthermore, as regards disease management programs in particular, the more accurately targeted the program the more likely it is to effect a behavioral change in the patient.

Reasons to Purchase

Learn how communication between patients, physicians and the pharmaceutical industry impacts rates of adherence
Assess pharmaceutical industry-specific issues surrounding disease management and drug adherence in the US and 5EU
Gain insight into the role of technology in disease management and drug adherence